
## Nicholas Lintzeris

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/109997/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings. Addiction, 2022, 117, 382-391.	3.3	22
2	Opioid agonist treatment and patient outcomes during the <scp>COVID</scp> â€19 pandemic in south east Sydney, Australia. Drug and Alcohol Review, 2022, 41, 1009-1019.	2.1	25
3	Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. International Journal of Drug Policy, 2022, 100, 103492.	3.3	22
4	Determination of contaminants in artisanal cannabis products used for childhood epilepsy in the Australian community: A sub-analysis of the â€~PELICAN' study. Epilepsy and Behavior, 2022, 127, 108496.	1.7	7
5	Overdose and takeâ€home naloxone in emergency settings: A pilot study examining feasibility of delivering brief interventions addressing overdose prevention with †takeâ€home naloxone' in emergency departments. EMA - Emergency Medicine Australasia, 2022, 34, 509-518.	1.1	5
6	Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition. Drug and Alcohol Review, 2022, 41, 1095-1108.	2.1	11
7	What do general practitioners want from specialist alcohol and other drug services? A qualitative study of New South Wales metropolitan general practitioners. Drug and Alcohol Review, 2022, 41, 1152-1160.	2.1	4
8	Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial. Drug and Alcohol Dependence, 2022, 234, 109388.	3.2	1
9	Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials. Addiction Biology, 2022, 27, e13125.	2.6	18
10	The Overdose Response with Take Home Naloxone ( <scp>ORTHN</scp> ) project: Evaluation of health worker training, attitudes and perceptions. Drug and Alcohol Review, 2022, 41, 1085-1094.	2.1	1
11	Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies. Neuropsychopharmacology, 2022, 47, 1315-1330.	5.4	28
12	Response to Steele and Acheson. Drug and Alcohol Review, 2022, , .	2.1	0
13	Self-reported challenges obtaining ongoing prescription opioids among Australians with chronic non-cancer pain. International Journal of Drug Policy, 2022, 105, 103708.	3.3	2
14	Assessing the concurrent validity, interâ€rater reliability and test–reâ€ŧest reliability of the Australian Treatment Outcomes Profile (ATOP) in alcohol and opioid treatment populations. Addiction, 2021, 116, 1245-1255.	3.3	9
15	The effect of daily aerobic cycling exercise on sleep quality during inpatient cannabis withdrawal: A randomised controlled trial. Journal of Sleep Research, 2021, 30, e13211.	3.2	3
16	Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018. JAMA Network Open, 2021, 4, e213059.	5.9	4
17	Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine. JAMA Network Open, 2021, 4, e219041.	5.9	55
18	Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study. BMJ Open, 2021, 11, e044696.	1.9	11

#	Article	IF	CITATIONS
19	Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges. Journal of Substance Abuse Treatment, 2021, 124, 108221.	2.8	13
20	Determining clinical cutoff scores for the Australian Treatment Outcomes Profile psychological health, physical health and quality of life questions. Drug and Alcohol Review, 2021, , .	2.1	4
21	Opioid prescribing in Australia: too much and not enough. Medical Journal of Australia, 2021, 215, 117-118.	1.7	3
22	Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia. Drug and Alcohol Dependence, 2021, 227, 108959.	3.2	33
23	Managing opioid withdrawal precipitated by buprenorphine with buprenorphine. Drug and Alcohol Review, 2021, 40, 567-571.	2.1	19
24	Clinical correlates and outcomes associated with pregabalin use among people prescribed opioids for chronic nonâ€cancer pain: A fiveâ€year prospective cohort study. British Journal of Clinical Pharmacology, 2021, 87, 3092-3104.	2.4	9
25	Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a crossâ€sectional study in three Australian cities. Addiction, 2021, 116, 1482-1494.	3.3	3
26	Development of a Brief Patient-Administered Screening Tool for Prescription Opioid Dependence for Primary Care Settings. Pain Medicine, 2020, 21, e79-e88.	1.9	8
27	Acute Experimental Pain Responses in Methadone- and Buprenorphine/Naloxone-Maintained Patients Administered Additional Opioid or Gabapentin: A Double-Blind Crossover Pilot Study. Pain Medicine, 2020, 21, 1188-1198.	1.9	3
28	Clinical Significance and Outcomes in Trial of Nabiximols for Treatment of Cannabis Dependence—Reply. JAMA Internal Medicine, 2020, 180, 163.	5.1	0
29	Designing, implementing and evaluating the overdose response with takeâ€home naloxone model of care: An evaluation of client outcomes and perspectives. Drug and Alcohol Review, 2020, 39, 55-65.	2.1	12
30	Driving-Related Behaviours, Attitudes and Perceptions among Australian Medical Cannabis Users: Results from the CAMS 18-19 Survey. Accident Analysis and Prevention, 2020, 148, 105784.	5.7	24
31	Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study. EClinicalMedicine, 2020, 28, 100592.	7.1	16
32	Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial. Drug and Alcohol Dependence, 2020, 215, 108220.	3.2	19
33	Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study. BMJ Open, 2020, 10, e034389.	1.9	9
34	Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduction Journal, 2020, 17, 26.	3.2	187
35	Providing take home naloxone needs to be improved to prevent opioid overdose deaths. Medical Journal of Australia, 2020, 212, 307-308.	1.7	2
36	Assessing the validity of the Australian Treatment Outcomes Profile for telephone administration in drug health treatment populations. Drug and Alcohol Review, 2020, 39, 441-446.	2.1	15

#	Article	IF	CITATIONS
37	Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review. CNS Drugs, 2020, 34, 337-365.	5.9	105
38	Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence. Drug and Alcohol Review, 2020, 39, 356-364.	2.1	7
39	Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). Harm Reduction Journal, 2020, 17, 37.	3.2	72
40	Concerns and Help-Seeking Among Patients Using Opioids for Management of Chronic Noncancer Pain. Pain Medicine, 2019, 20, 758-769.	1.9	9
41	Estimating Centre for Disease Control and Preventionâ€defined overdose risk in people prescribed opioids for chronic nonâ€cancer pain: implications for takeâ€home naloxone provision. Internal Medicine Journal, 2019, 49, 1054-1055.	0.8	10
42	Nabiximols for the Treatment of Cannabis Dependence. JAMA Internal Medicine, 2019, 179, 1242.	5.1	68
43	Detection of Δ <sup>9</sup> THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two pointâ€ofâ€collection testing devices. Drug Testing and Analysis, 2019, 11, 1486-1497.	2.6	32
44	Longâ€ŧerm safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult outâ€patients with opioid use disorder. Addiction, 2019, 114, 1416-1426.	3.3	75
45	Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology, 2019, 236, 2713-2724.	3.1	130
46	Antidepressant Use Among People Prescribed Opioids for Chronic Noncancer Pain. Pain Medicine, 2019, 20, 2450-2458.	1.9	12
47	Regulatory and other responses to the pharmaceutical opioid problem. Medical Journal of Australia, 2019, 210, 6.	1.7	36
48	Survey of Australian psychiatrists' and psychiatry trainees' knowledge about and attitudes towards medicinal cannabinoids. Australasian Psychiatry, 2019, 27, 80-85.	0.7	21
49	Transferring Patients From Methadone to Buprenorphine: The Feasibility and Evaluation of Practice Guidelines. Journal of Addiction Medicine, 2018, 12, 234-240.	2.6	18
50	The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. Lancet Psychiatry,the, 2018, 5, 155-166.	7.4	28
51	Does training people to administer takeâ€home naloxone increase their knowledge? Evidence from Australian programs. Drug and Alcohol Review, 2018, 37, 472-479.	2.1	27
52	Findings and lessons learnt from implementing Australia's first health service based takeâ€home naloxone program. Drug and Alcohol Review, 2018, 37, 464-471.	2.1	34
53	Cognitive screening in substance users: Diagnostic accuracies of the Mini-Mental State Examination, Addenbrooke's Cognitive Examination–Revised, and Montreal Cognitive Assessment. Journal of Clinical and Experimental Neuropsychology, 2018, 40, 107-122.	1.3	38
54	Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids. Pain Medicine, 2018, 19, 533-540.	1.9	32

#	Article	IF	CITATIONS
55	Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence. Drug and Alcohol Review, 2018, 37, 887-896.	2.1	5
56	Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV). BMJ Open, 2018, 8, e020745.	1.9	16
57	Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health, The, 2018, 3, e341-e350.	10.0	172
58	An overview of takeâ€home naloxone programs in Australia. Drug and Alcohol Review, 2018, 37, 440-449.	2.1	37
59	Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol. BMC Psychiatry, 2018, 18, 140.	2.6	17
60	LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence. BMJ Open, 2018, 8, e020723.	1.9	11
61	Medicinal cannabis in Australia, 2016: the Cannabis as Medicine Survey (CAMSâ€16). Medical Journal of Australia, 2018, 209, 211-216.	1.7	66
62	Supervised Injectable Opioid Treatment for the Management of Opioid Dependence. Drugs, 2018, 78, 1339-1352.	10.9	22
63	Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis. Pharmacoeconomics, 2018, 36, 67-78.	3.3	21
64	Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series. Drug and Alcohol Review, 2017, 36, 311-316.	2.1	3
65	Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment. Pharmacoepidemiology and Drug Safety, 2017, 26, 587-591.	1.9	39
66	Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial. Drug and Alcohol Dependence, 2017, 174, 181-191.	3.2	29
67	An Australian nationwide survey on medicinal cannabis use for epilepsy: History of antiepileptic drug treatment predicts medicinal cannabis use. Epilepsy and Behavior, 2017, 70, 334-340.	1.7	55
68	Opioid Agonist Treatment for Patients With Dependence on Prescription Opioids. JAMA - Journal of the American Medical Association, 2017, 317, 967.	7.4	55
69	Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. Neuropsychopharmacology, 2017, 42, 1752-1765.	5.4	190
70	Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment. Drug and Alcohol Dependence, 2017, 181, 132-139.	3.2	27
71	Randomised controlled trial (RCT) of daily aerobic exercise for inpatient cannabis withdrawal: A study protocol. Mental Health and Physical Activity, 2017, 13, 57-67.	1.8	5
72	Urinary cannabinoid levels during nabiximols (Sativex®)-medicated inpatient cannabis withdrawal. Forensic Toxicology, 2017, 35, 33-44.	2.4	19

#	Article	IF	CITATIONS
73	The Australian Treatment Outcomes Profile instrument as a clinical tool for older alcohol and other drug clients: A validation study. Drug and Alcohol Review, 2016, 35, 673-677.	2.1	15
74	Sleep Quality Among People Living With Chronic Noncancer Pain. Clinical Journal of Pain, 2016, 32, 380-387.	1.9	10
75	Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic noncancer pain: do different measures identify the same patients?. Pain, 2016, 157, 1489-1498.	4.2	43
76	Substance use, health status and service utilisation of older clients attending specialist drug and alcohol services. Drug and Alcohol Review, 2016, 35, 223-231.	2.1	14
77	Study protocol: a dose-escalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependence. BMC Psychiatry, 2016, 16, 428.	2.6	8
78	Development of a brief tool for monitoring aberrant behaviours among patients receiving long-term opioid therapy: The Opioid-Related Behaviours In Treatment (ORBIT) scale. Drug and Alcohol Dependence, 2016, 159, 42-52.	3.2	27
79	Recommendations for the Prevention, Detection, Treatment and Management of Prescription Opioid Analgesic Dependence: Outcomes From the Opioid Analgesic Dependence Education Nexus (OPEN) Meeting. International Journal of Mental Health and Addiction, 2016, 14, 313-321.	7.4	12
80	Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia. Drug and Alcohol Review, 2016, 35, 83-91.	2.1	15
81	Alprazolam use and related harm among opioid substitution treatment clients – 12 months follow up after regulatory rescheduling. International Journal of Drug Policy, 2016, 36, 104-111.	3.3	18
82	Pain, alcohol use disorders and risky patterns of drinking among people with chronic non-cancer pain receiving long-term opioid therapy. Drug and Alcohol Dependence, 2016, 162, 79-87.	3.2	40
83	Treating codeine dependence with buprenorphine: Dose requirements and induction outcomes from a retrospective case series in <scp>N</scp> ew <scp>S</scp> outh <scp>W</scp> ales, <scp>A</scp> ustralia. Drug and Alcohol Review, 2016, 35, 70-75.	2.1	7
84	The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations. Drug and Alcohol Review, 2015, 34, 603-610.	2.1	8
85	Injecting buprenorphineâ€naloxone film: Findings from an explorative qualitative study. Drug and Alcohol Review, 2015, 34, 623-629.	2.1	6
86	A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamperâ€resistant formulation of controlledâ€release oxycodone. Pharmacoepidemiology and Drug Safety, 2015, 24, 1321-1333.	1.9	4
87	The Effects of Lithium Carbonate Supplemented with Nitrazepam on Sleep Disturbance during Cannabis Abstinence. Journal of Clinical Sleep Medicine, 2015, 11, 1153-1162.	2.6	16
88	Pharmaceutical Opioid Use and Dependence among People Living with Chronic Pain: Associations Observed within the Pain and Opioids in Treatment (POINT) Cohort. Pain Medicine, 2015, 16, 1745-1758.	1.9	78
89	Benzodiazepine Use among Chronic Pain Patients Prescribed Opioids: Associations with Pain, Physical and Mental Health, and Health Service Utilization. Pain Medicine, 2015, 16, 356-366.	1.9	102
90	Reversal of central sleep apnoea with change from methadone to buprenorphine-naloxone: a case report. European Respiratory Journal, 2015, 46, 1202-1205.	6.7	11

#	Article	IF	CITATIONS
91	Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): a cohort study. Lancet Psychiatry,the, 2015, 2, 314-322.	7.4	55
92	Experience of adjunctive cannabis use for chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study. Drug and Alcohol Dependence, 2015, 147, 144-150.	3.2	97
93	The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. Drug and Alcohol Dependence, 2015, 151, 56-67.	3.2	29
94	The Pain and Opioids IN Treatment study. Pain, 2015, 156, 231-242.	4.2	104
95	Screening for alcohol and substance use for older people in geriatric hospital and community health settings. International Psychogeriatrics, 2015, 27, 157-166.	1.0	22
96	Evaluating the potential impact of a reformulated version of oxycodone upon tampering, nonâ€adherence and diversion of opioids: the <scp>N</scp> ational <scp>O</scp> pioid <scp>M</scp> edications <scp>A</scp> buse <scp>D</scp> eterrence ( <scp>NOMAD</scp> ) study protocol. Addiction, 2015, 110, 226-237.	3.3	19
97	Drug use, health and social outcomes of hard-to-treat heroin addicts receiving supervised injectable opiate treatment: secondary outcomes from the Randomized Injectable Opioid Treatment Trial (RIOTT). Addiction, 2015, 110, 479-490.	3.3	23
98	Comparing treatmentâ€seeking codeine users and strong opioid users: Findings from a novel case series. Drug and Alcohol Review, 2015, 34, 304-311.	2.1	25
99	The characteristics of a cohort who tamper with prescribed and diverted opioid medications. Journal of Substance Abuse Treatment, 2015, 58, 51-61.	2.8	20
100	Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal. JAMA Psychiatry, 2014, 71, 281.	11.0	209
101	Diversion of prescribed opioids by people living with chronic pain: Results from an <scp>A</scp> ustralian community sample. Drug and Alcohol Review, 2014, 33, 27-32.	2.1	11
102	Validation and implementation of the <scp>A</scp> ustralian Treatment Outcomes Profile in specialist drug and alcohol settings. Drug and Alcohol Review, 2014, 33, 33-42.	2.1	77
103	Buprenorphine Diversion and Misuse in Outpatient Practice. Journal of Addiction Medicine, 2014, 8, 327-332.	2.6	6
104	The diversion and injection of a buprenorphine-naloxone soluble film formulation. Drug and Alcohol Dependence, 2014, 136, 21-27.	3.2	43
105	Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting. Psychopharmacology, 2014, 231, 4623-4636.	3.1	29
106	Cohort protocol paper: The Pain and Opioids In Treatment (POINT) study. BMC Pharmacology & Toxicology, 2014, 15, 17.	2.4	39
107	A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: Do stable patients receive more unsupervised doses?. Drug and Alcohol Dependence, 2014, 142, 46-55.	3.2	14
108	Authors' reply. British Journal of Psychiatry, 2014, 204, 241-242.	2.8	1

#	Article	IF	CITATIONS
109	Exercise increases plasma THC concentrations in regular cannabis users. Drug and Alcohol Dependence, 2013, 133, 763-767.	3.2	34
110	Correlates of pain in an inâ€treatment sample of opioidâ€dependent people. Drug and Alcohol Review, 2013, 32, 489-494.	2.1	8
111	An Evaluation of the Prescription of Opioids for Chronic Nonmalignant Pain by Australian General Practitioners. Pain Medicine, 2013, 14, 62-74.	1.9	19
112	Treatment expectations and satisfaction of treatmentâ€refractory opioidâ€dependent patients in RIOTT, the <scp>R</scp> andomised <scp>I</scp> njectable <scp>O</scp> piate <scp>T</scp> reatment <scp>T</scp> rial, the <scp>UK</scp> 's first supervised injectable maintenance clinics. Drug and Alcohol Review, 2013, 32, 566-573.	2.1	15
113	An examination of the influences on New South Wales general practitioners regarding the provision of opioid substitution therapy. Drug and Alcohol Review, 2013, 32, n/a-n/a.	2.1	10
114	Cost-effectiveness of injectable opioid treatment <i>v</i> . oral methadone for chronic heroin addiction. British Journal of Psychiatry, 2013, 203, 341-349.	2.8	66
115	The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids. Medical Journal of Australia, 2013, 199, 696-699.	1.7	24
116	Realâ€ŧime monitoring of Schedule 8 medicines in Australia: evaluation is essential. Medical Journal of Australia, 2013, 198, 80-81.	1.7	32
117	Unplanned pregnancy and contraceptive use in women attending drug treatment services. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2012, 52, 146-150.	1.0	85
118	Reluctant to train, reluctant to prescribe: barriers to general practitioner prescribing of opioid substitution therapy. Australian Journal of Primary Health, 2012, 18, 346.	0.9	15
119	The health impacts of khat: a qualitative study among Somaliâ€Australians. Medical Journal of Australia, 2011, 195, 666-669.	1.7	51
120	Investigating the effect on public behaviour of patients of a Medically Supervised Injectable Maintenance Clinic. Drugs and Alcohol Today, 2011, 11, 204-209.	0.7	1
121	Methadone and buprenorphine prescribing patterns of Victorian general practitioners: Their first 5 years after authorisation. Drug and Alcohol Review, 2011, 30, 355-359.	2.1	14
122	Methadone maintenance, QTc and torsade de pointes: Who needs an electrocardiogram and what is the prevalence of QTc prolongation?. Drug and Alcohol Review, 2011, 30, 388-396.	2.1	57
123	Pharmaceutical opioid analgesic and heroin dependence: How do treatmentâ€seeking clients differ in Australia?. Drug and Alcohol Review, 2011, 30, 291-299.	2.1	28
124	"Should I stay or should I go?―Coming off methadone and buprenorphine treatment. International Journal of Drug Policy, 2011, 22, 77-81.	3.3	53
125	Benzodiazepines, Methadone and Buprenorphine: Interactions and Clinical Management. American Journal on Addictions, 2010, 19, 59-72.	1.4	92
126	The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic. Addiction, 2010, 105, 329-334.	3.3	20

#	Article	IF	CITATIONS
127	Commentary on Blanken <i>et al.</i> (2010): Longâ€ŧerm heroinâ€₅ssisted treatment—some more question and answers. Addiction, 2010, 105, 309-310.	15 <sub>3.3</sub>	1
128	Forming a national multicentre collaboration to conduct clinical trials: Increasing highâ€quality research in the drug and alcohol field. Drug and Alcohol Review, 2010, 29, 469-474.	2.1	6
129	The community impact of RIOTT, a medically supervised injectable maintenance clinic in south London. Mental Health and Substance Use: Dual Diagnosis, 2010, 3, 248-259.	0.5	4
130	Bioavailability of Buprenorphine from Crushed and Whole Buprenorphine (Subutex) Tablets. European Addiction Research, 2010, 16, 85-90.	2.4	17
131	Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet, The, 2010, 375, 1885-1895.	13.7	166
132	Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist–antagonist formulation. Medical Journal of Australia, 2009, 191, 161-165.	1.7	40
133	Why do patients report transferring between methadone and buprenorphine?. Drug and Alcohol Review, 2009, 28, 686-687.	2.1	10
134	Fastâ€ŧracking implementation through trial design: the case of buprenorphine treatment in Victoria. Australian and New Zealand Journal of Public Health, 2009, 33, 34-39.	1.8	3
135	Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. Journal of Substance Abuse Treatment, 2009, 37, 95-100.	2.8	45
136	Prescription of Heroin for the Management of Heroin Dependence. CNS Drugs, 2009, 23, 463-476.	5.9	48
137	[Commentary] FUTURE CHALLENGES FOR HEROIN AND OTHER OPIOID SUBSTITUTION TREATMENT. Addiction, 2008, 103, 967-968.	3.3	12
138	THE USE OF SUBLINGUAL BUPRENORPHINE–NALOXONE FOR REVERSING HEROIN OVERDOSE: A HIGHâ€RISK STRATEGY THAT SHOULD NOT BE RECOMMENDED. Addiction, 2008, 103, 2065-2066.	3.3	6
139	Unplanned admissions to two Sydney public hospitals after naltrexone implants. Medical Journal of Australia, 2008, 188, 441-444.	1.7	23
140	Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients. Drug and Alcohol Dependence, 2007, 91, 187-194.	3.2	92
141	Maintenance Pharmacotherapy for Opioid Dependence and SF-36 Health Status: A Comparison With General Population Norms and Other Chronic Disorders. Addictive Disorders and Their Treatment, 2006, 5, 155-164.	0.5	15
142	Interactions on Mixing Diazepam With Methadone or Buprenorphine in Maintenance Patients. Journal of Clinical Psychopharmacology, 2006, 26, 274-283.	1.4	63
143	Feasibility and Acceptability of an Intranasal Diamorphine Spray as an Alternative to Injectable Diamorphine for Maintenance Treatment. European Addiction Research, 2006, 12, 91-95.	2.4	16
144	Effects of Pharmacotherapies for Opioid Dependence on Participants' Criminal Behaviour and Expenditure on Illicit Drugs: An Australian National Evaluation (NEPOD). Australian and New Zealand Journal of Criminology, 2006, 39, 171-189.	2.5	11

#	Article	IF	CITATIONS
145	Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project. Addictive Behaviors, 2005, 30, 443-456.	3.0	23
146	Implementing Buprenorphine Treatment in Community Settings in Australia: Experiences from the Buprenorphine Implementation Trial. American Journal on Addictions, 2004, 13, S29-S41.	1.4	54
147	Methadone syrup injection in Australia: a sentinel finding?. Addiction, 2003, 98, 385-386.	3.3	5
148	A randomized trial comparing levo-alpha acetylmethadol with methadone maintenance for patients in primary care settings in Australia. Addiction, 2003, 98, 1605-1613.	3.3	20
149	Buprenorphine dosing regime for inpatient heroin withdrawal: a symptom-triggered dose titration study. Drug and Alcohol Dependence, 2003, 70, 287-294.	3.2	24
150	Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions. Drug and Alcohol Dependence, 2003, 71, 49-55.	3.2	48
151	A randomized controlled trial of buprenorphine in the management of shortâ€ŧerm ambulatory heroin withdrawal. Addiction, 2002, 97, 1395-1404.	3.3	91
152	Buprenorphine dosing regime in the management of out-patient heroin withdrawal. Drug and Alcohol Review, 2002, 21, 39-45.	2.1	19
153	Severe opiate withdrawal in a heroin user precipitated by a massive buprenorphine dose. Medical Journal of Australia, 2002, 176, 166-7.	1.7	21
154	Trends in licit opioid use in Australia, 1984â€1998: comparative analysis of international and jurisdictional data. Medical Journal of Australia, 2000, 173, 524-527.	1.7	21
155	Methadone injecting in Australia: a tale of two cities. Addiction, 1999, 94, 1175-1178.	3.3	32
156	Cultural Adaptation and Psychometric Validation of the Australian Treatment Outcomes Profile for the Greek Population. International Journal of Mental Health and Addiction, 0, , 1.	7.4	1